Prophylactic use of steroids and/or an IL-6 inhibitor can reduce the likelihood of severe adverse events in patients receiving axicabtagene ciloleucel (Yescarta) for large B-cell lymphoma (LBCL), a cohort analysis from the ZUMA-1 trial finds. Writing in the British Journal of Haematology, the researchers noted that cytokine release syndrome (CRS) and neurologic events (NEs) were ...
Prophylactic steroids can prevent CAR T-cell toxicity
By Nicola Garrett
29 Jul 2021